Skip to main content
main-content

Oncology news

19-04-2017 | Melanoma | Highlight | Article

Editor's pick

Surgical resection still important in abdominal melanoma metastases

Patients who undergo surgical resection of abdominal visceral melanoma metastases have significantly better overall survival than those who do not, and the outcome is not greatly improved by modern systemic treatments, study findings indicate.

Source:

JAMA Surg 2017; Advance online publication

24-04-2017 | Oncology | News | Article

News in brief

Survival comparable with bladder-sparing trimodal therapy and radical cystectomy

A propensity score-matched cohort analysis finds no significant difference between bladder-sparing trimodal therapy and radical cystectomy with respect to survival in patients with muscle-invasive bladder cancer.

21-04-2017 | Oncology | News | Article

Caution needed when using PFS as an OS surrogate in immunotherapy trials

In phase II and III trials of oncologic immunotherapeutic agents, treatment effect sizes are on average larger for progression-free survival than for overall survival, find researchers who question the value of using progression-free survival as a surrogate for overall survival in such trials.

Source:

J Clin Oncol 2017; Advance online publication

19-04-2017 | Chronic myeloid leukaemia | News | Article

First-line generic imatinib offers ‘suboptimal efficacy’

For patients undergoing front-line treatment for chronic myeloid leukemia, generic treatment may be less effective than the branded agent, researchers suggest, but treatment efficacy is maintained in patients who switch from a branded to a generic formulation.

Source:

Clin Lymphoma Myeloma Leuk 2017; Advance online publication

18-04-2017 | Oncology | News | Article

Vinflunine maintenance shows promise in advanced urothelial carcinoma

Maintenance therapy with vinflunine plus best supportive care significantly delays disease progression over best supportive care alone in patients with transitional cell carcinoma of the urothelial tract, study data show.

Source:

Lancet Oncol 2017; Advance online publication

Positive long-Term Imatinib Findings For Advanced GIST Patients

Progression-free survival and overall survival results over 10 years of survival are reported for gastrointestinal stromal tumor patients with locally advanced or metastatic disease

Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

approvalsWatch: Oncology

ESMO 2016 coverage

medwireNews@ESMO2016

medwireNews brings you news and conference reports from the ESMO 2016 Congress, held in Copenhagen, Denmark.

Click through to read the full reports of the latest research.

Twitter Icon Follow medwireNews

Click here
image credits